Aura Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Aura Biosciences Inc. (NASDAQ: AURA) announced CEO Elisabet de los Pinos will participate in investor conferences. The company develops virus-like drug conjugate therapies for oncology. Webcasts of the conferences will be available on the company's website.

BOSTON--(BUSINESS WIRE)-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:

• 44th Annual TD Cowen Health Care Conference on Monday, March 4, 2024.
  Fireside Chat at 1:30 p.m. ET.
• Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024.
  Fireside Chat at 3:40 p.m. ET.

The live webcasts of both fireside chats will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing VDCs, a novel class of therapies, for the treatment of multiple oncology indications. Aura’s lead VDC candidate, belzupacap sarotalocan (bel-sar; AU-011), consists of a virus-like particle conjugated with an anti-cancer agent. Bel-sar is designed to selectively target and destroy cancer cells and activate the immune system with the potential to create long-lasting, anti-tumor immunity. Bel-sar is currently in development for ocular cancers, and Aura is enrolling patients in the global Phase 3 trial evaluating first-line treatment of early-stage choroidal melanoma, a vision- and life-threatening form of eye cancer where the standard of care with radiotherapy leaves patients with severe comorbidities, including significant vision loss. Aura plans to pursue development of bel-sar across its ocular oncology franchise including for the treatment of patients with choroidal metastasis. In addition, leveraging Aura’s technology platform, Aura is developing bel-sar more broadly across multiple cancers, including in patients with non-muscle invasive and muscle invasive bladder cancer. Aura is headquartered in Boston, MA.

For more information, visit aurabiosciences.com, or follow us on X, formerly Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240226370868/en/

Investors and Media:

Alex Dasalla

Head of Investor Relations and Corporate Communications

adasalla@aurabiosciences.com

Source: Aura Biosciences Inc.

FAQ

When will CEO Elisabet de los Pinos participate in investor conferences?

CEO Elisabet de los Pinos will participate in the 44th Annual TD Cowen Health Care Conference on March 4, 2024, and the Leerink Partners Global Biopharma Conference on March 12, 2024.

What type of therapies does Aura Biosciences Inc. develop?

Aura Biosciences Inc. develops a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications.

Where can the webcasts of the fireside chats be accessed?

The webcasts will be available on the 'Investors & Media' page under the 'Events & Presentations' section of the company's website at https://ir.aurabiosciences.com/events-and-presentations.

For how long will the webcast replays be archived?

The webcast replays will be archived for 90 days following the presentation date.